logo-loader
viewChina Biologic Products

China Biologic beats analyst expectations and swings to third quarter profit

profits_up_350_4ce2d52c4df0f.jpg

China Biologic Products (Nasdaq: CBPO), a Chinese biopharmaceutical company specializing in plasma-based products, said today that it swung to a profit for the third quarter on aggressive pricing strategies.

For the third quarter, profits attributable to the company were $13.7 million, or 53 cents per diluted share, compared to a loss of $6.2 million, or 29 cents per diluted share, for the year-ago period.

Excluding non-cash expenses and derivative gains and losses, third quarter profits attributable to the company were $10.5 million, or 39 cents per diluted share, up from $7.1 million, or 33 cents per diluted share, in the third quarter of 2009.

Meanwhile, third quarter revenues increased 33% year-over-year to $36 million, driven mainly by product price increases.

The results trumped analyst estimates, which typically exclude special items, of 32 cents per diluted share on revenues of $33.5 million.

The firm's antibody products, which make up half of the company's third quarter revenue, had average price increases ranging from 6.2% to 55.8%.

At quarter end, the company had about $123 million in current assets, about $64 million of which was in cash.  Total liabilities stood at roughly $67 million.

China Biologic also reaffirmed its guidance for 2010 adjusted profits between $34 million and $36 million.  Revenues for fiscal 2010 are expected to come in between $142 million and $149 million.

Since the news, the company's shares have rallied 3.2% to trade at $11.13 as of 1:48 pm EST.

Quick facts: China Biologic Products

Price: 106.03 USD

NASDAQ:CBPO
Market: NASDAQ
Market Cap: $4.08 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Alpha Growth PLC’s Danny Swick and Austin King describe the BlackOak Alpha...

Alpha Growth PLC (LON: ALGW) Chief Operations Officer Danny Swick and Investor Relations Officer Austin King joined Steve Darling from Proactive with news the company has started their BlackOak Alpha Growth Fund which is their life settlement investment fund geared toward U.S. investors. Both...

3 hours, 37 minutes ago

2 min read